1 |
Clinical pipeline report, company report or official report of Klus Pharma
|
2 |
ClinicalTrials.gov (NCT04659603) Open-label, Multi-cohort, Phase 2 Trial, Evaluating the Efficacy and Safety of Tusamitamab Ravtansine (SAR408701) Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors. U.S.National Institutes of Health.
|
3 |
ClinicalTrials.gov (NCT05094336) A Phase 1/1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 193 Alone and in Combination With Docetaxel in Subjects With Advanced MTAP-null Solid Tumors. U.S.National Institutes of Health.
|
4 |
ClinicalTrials.gov (NCT04939701) A Phase 1/2 Open-label Study Investigating the Safety, Tolerability and Efficacy of ASP0739 as a Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors Known to Express NY-ESO-1. U.S.National Institutes of Health.
|
5 |
ClinicalTrials.gov (NCT05123482) A Phase I/IIa Multi-center, Open-label Master Protocol to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Antitumor Activity of AZD8205 in Participants With Advanced or Metastatic Solid Malignancies. U.S.National Institutes of Health.
|
6 |
ClinicalTrials.gov (NCT05397171) A Phase I/IIa First-in-human, Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of AZD8853 in Participants With Selected Advanced/Metastatic Solid Tumours. U.S.National Institutes of Health.
|
7 |
ClinicalTrials.gov (NCT05417594) A Modular Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (CERTIS1). U.S.National Institutes of Health.
|
8 |
ClinicalTrials.gov (NCT03289962) A Phase 1a/1b Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of RO7198457 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Tumors. U.S.National Institutes of Health.
|
9 |
ClinicalTrials.gov (NCT05262530) First-in-human, Open-label, Multicenter, Phase I/IIa, Dose Escalation Trial With Expansion Cohorts to Evaluate Safety and Preliminary Efficacy of BNT142 in Patients With CLDN6-positive Advanced Solid Tumors. U.S.National Institutes of Health.
|
10 |
ClinicalTrials.gov (NCT04455620) Phase I/IIa, First-in-human, Open-label, Dose Escalation Trial With Expansion Cohorts to Evaluate Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BNT151 as a Monotherapy and in Combination With Other Anti-cancer Agents in Patients With Solid Tumors. U.S.National Institutes of Health.
|
11 |
ClinicalTrials.gov (NCT04503278) Phase I/IIa, First-in-human (FIH), Open-label, Dose Escalation Trial With Expansion Cohorts to Evaluate Safety and Preliminary Efficacy of CLDN6 CAR-T With or Without CLDN6 RNA-LPX in Patients With CLDN6-positive Relapsed or Refractory Advanced Solid Tumors. U.S.National Institutes of Health.
|
12 |
Clinical pipeline report, company report or official report of GlaxoSmithKline
|
13 |
ClinicalTrials.gov (NCT05533697) Phase 1/2 Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors. U.S.National Institutes of Health.
|
14 |
ClinicalTrials.gov (NCT04913337) A Phase 1/2 Dose Escalation/Expansion Study of NGM707 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies. U.S.National Institutes of Health.
|
15 |
ClinicalTrials.gov (NCT05450562) A Phase 1/2 Open-label, First-in-human, Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of SAR444200-based Regimen in Participants With Advanced Solid Tumors. U.S.National Institutes of Health.
|
16 |
ClinicalTrials.gov (NCT05584670) A Phase 1/2, Open Label, First-in-human, Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of SAR445877 Administered as Monotherapy in Adults With Advanced Solid Tumors. U.S.National Institutes of Health.
|
17 |
ClinicalTrials.gov (NCT05220098) A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-280 in Patients With Unresectable Locally Advanced or Metastatic Cancer. U.S.National Institutes of Health.
|
18 |
Clinical pipeline report, company report or official report of Tessa Therapeutics
|
19 |
ClinicalTrials.gov (NCT04673942) A Phase 1/2, First in Human, Study to Evaluate the Safety and Tolerability of AdAPT-001 in Subjects With Refractory Solid Tumors. U.S.National Institutes of Health.
|
20 |
ClinicalTrials.gov (NCT05083481) A Phase 1/2 Study of ASP1570 as Monotherapy and in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors. U.S.National Institutes of Health.
|
21 |
ClinicalTrials.gov (NCT04972110) Phase 1b/2 Study of ATR InhibiTor RP-3500 and PARP Inhibitor Combinations in Patients With Molecularly Selected Cancers (ATTACC). U.S.National Institutes of Health.
|
22 |
ClinicalTrials.gov (NCT04731467) A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CM24 in Combination With Nivolumab in Adults With Advanced Solid Tumors. U.S.National Institutes of Health.
|
23 |
ClinicalTrials.gov (NCT03543813) A Phase 1-2, First-in-Human Study of CX-2029 in Adults With Metastatic or Locally Advanced Unresectable Solid Tumors or Diffuse Large B-cell Lymphomas (PROCLAIM-CX-2029). U.S.National Institutes of Health.
|
24 |
ClinicalTrials.gov (NCT04157517) An Open-Label, Dose-Escalation Phase 1b/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Modakafusp Alfa (TAK-573) as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced or Metastatic Solid Tumors. U.S.National Institutes of Health.
|
25 |
ClinicalTrials.gov (NCT05205850) An Open, Multi-center Phase I/IIa Clinical Study of RC118 for Injection in Patients With Locally Advanced Unresectable or Metastatic Malignant Solid Tumors With Positive Expression of Claudin 18.2. U.S.National Institutes of Health.
|
26 |
ClinicalTrials.gov (NCT04844073) A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-186 (Also Known as MVC-101), An EGFR x CD3 COnditional Bispecific Redirected Activation (COBRA) Protein in Patients With Unresectable Locally Advanced or Metastatic Cancer. U.S.National Institutes of Health.
|
27 |
Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight
|
28 |
ClinicalTrials.gov (NCT04597411) AcTION: A Phase I Study of [225Ac]Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer With or Without Prior [177Lu]Lu-PSMA-617 Radioligand Therapy. U.S.National Institutes of Health.
|
29 |
ClinicalTrials.gov (NCT04319757) A Phase I, Open Label, Dose Escalation Study of ACE1702 Cell Immunotherapy in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors. U.S.National Institutes of Health.
|
30 |
ClinicalTrials.gov (NCT05317078) Phase 1 First-In-Human Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 794 in Participants With Claudin 6-positive Advanced/Metastatic Non-small Cell Lung Cancer, Epithelial Ovarian Cancer, and Other Malignant Solid Tumor Indications. U.S.National Institutes of Health.
|
31 |
ClinicalTrials.gov (NCT04975958) An Open-Label, Multicenter, Phase 1a Study of AN2025 and AN0025 in Double Combination With Atezolizumab and in Triple Combination With Atezolizumab in Patients With Advanced Solid Tumors. U.S.National Institutes of Health.
|
32 |
ClinicalTrials.gov (NCT05646797) A Phase 1/1b Study of ASP2074 in Participants With Metastatic or Locally Advanced Solid Tumors. U.S.National Institutes of Health.
|
33 |
ClinicalTrials.gov (NCT05382559) A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation. U.S.National Institutes of Health.
|
34 |
ClinicalTrials.gov (NCT05647122) A Phase I, Multicenter, Open-label, First-in-Human, Dose Escalation and Expansion Study of AZD9592 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumors. U.S.National Institutes of Health.
|
35 |
ClinicalTrials.gov (NCT04257110) A First-in-human, Open Label, Multiple Dose, Dose Escalation and Cohort Expansion Phase I Study to Investigate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of BB-1701 in Subjects With Locally Advanced/Metastatic HER2 Expressing Solid Tumors. U.S.National Institutes of Health.
|
36 |
ClinicalTrials.gov (NCT04710043) Phase I, First-in-human, Open-label, Dose Escalation Trial to Evaluate Safety, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of BNT152+153 in Patients With Solid Tumors. U.S.National Institutes of Health.
|
37 |
ClinicalTrials.gov (NCT04625205) An Open-label, Phase I Study of NEO-PTC-01 in Patients With Advanced or Metastatic Melanoma. U.S.National Institutes of Health.
|
38 |
ClinicalTrials.gov (NCT05435339) First-in-Human, Open-label, Dose-Escalation Trial With an Expansion Cohort to Evaluate the Safety of GEN1053 as Monotherapy in Subjects With Malignant Solid Tumors. U.S.National Institutes of Health.
|
39 |
ClinicalTrials.gov (NCT03537690) A Phase I Study of FID-007 in Patients With Advanced Solid Tumors. U.S.National Institutes of Health.
|
40 |
Clinical pipeline report, company report or official report of GlaxoSmithKline
|
41 |
ClinicalTrials.gov (NCT05277051) A Phase 1 First-Time-in-Human, Open-Label Study of GSK4381562 Administered as Monotherapy and in Combination With Anticancer Agents in Participants With Selected Advanced Solid Tumors. U.S.National Institutes of Health.
|
42 |
ClinicalTrials.gov (NCT05311618) A Phase 1/1b Dose Escalation/Expansion Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors. U.S.National Institutes of Health.
|
43 |
ClinicalTrials.gov (NCT05215574) A Phase 1/1b Dose Escalation/Expansion Study of NGM831 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors. U.S.National Institutes of Health.
|
44 |
ClinicalTrials.gov (NCT03319459) FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors. U.S.National Institutes of Health.
|
45 |
ClinicalTrials.gov (NCT04628780) A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETIC, PHARMACODYNAMIC, AND ANTI-TUMOR ACTIVITY OF PF-07209960 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS. U.S.National Institutes of Health.
|
46 |
ClinicalTrials.gov (NCT05061537) A PHASE 1, OPEN-LABEL, DOSE ESCALATION AND EXPANSION STUDY EVALUATING THE SAFETY AND PHARMACODYNAMICS OF PF-07263689, EITHER ALONE OR IN COMBINATION WITH AN ANTI-PD-1 ANTIBODY, IN PREVIOUSLY TREATED PARTICIPANTS WITH SELECTED LOCALLY ADVANCED OR METASTATIC SOLID TUMORS. U.S.National Institutes of Health.
|
47 |
ClinicalTrials.gov (NCT05233436) A PHASE 1, OPEN-LABEL, DOSE ESCALATION AND EXPANSION STUDY OF PF-07265028 AS A SINGLE AGENT AND IN COMBINATION WITH SASANLIMAB EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTI-TUMOR ACTIVITY OF PF-07265028 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS. U.S.National Institutes of Health.
|
48 |
ClinicalTrials.gov (NCT04800822) A PHASE 1, OPEN-LABEL, MULTI-CENTER, DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY EVIDENCE OF ANTI-TUMOR ACTIVITY OF PF-07284892 (ARRY-558) AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORS. U.S.National Institutes of Health.
|
49 |
ClinicalTrials.gov (NCT05538130) A PHASE 1A/B OPEN-LABEL MASTER STUDY OF PF-07799544 AS A SINGLE-AGENT AND IN COMBINATION WITH OTHER TARGETED AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS. U.S.National Institutes of Health.
|
50 |
ClinicalTrials.gov (NCT05355701) A PHASE 1, OPEN-LABEL, DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND ANTI TUMOR ACTIVITY OF PF-07799933 (ARRY-440) AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 16 YEARS AND OLDER WITH ADVANCED SOLID TUMORS WITH BRAF ALTERATIONS. U.S.National Institutes of Health.
|
51 |
Clinical pipeline report, company report or official report of Roche
|
52 |
Clinical pipeline report, company report or official report of Sanofi
|
53 |
ClinicalTrials.gov (NCT05367635) A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of SKB315 for Injection in Patients With Advanced Solid Tumors Expressing Claudin18.2. U.S.National Institutes of Health.
|
54 |
ClinicalTrials.gov (NCT05164666) An Open-Label, Dose Escalation, Phase 1, First-in-Human Study of TAK-103 in Adult Patients With Mesothelin-Expressing Advanced or Metastatic Solid Tumors. U.S.National Institutes of Health.
|
55 |
ClinicalTrials.gov (NCT05070247) An Open-label, Dose Escalation and Expansion, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of TAK-500, a Novel Stimulator of Interferon Genes Agonist, as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Select Locally Advanced or Metastatic Solid Tumors. U.S.National Institutes of Health.
|
56 |
ClinicalTrials.gov (NCT05514717) A Phase 1, First-in-Human, Dose Escalation and Expansion, Multicenter Study of XMT-2056 in Participants With Advanced/Recurrent Solid Tumors That Express HER2. U.S.National Institutes of Health.
|
57 |
ClinicalTrials.gov (NCT04699929) A Open-Label, Phase I Dose Escalation Study to Evaluate the Safety, Tolerability,Efficacy and Pharmacokinetics of YH001 in Subjects With Advanced Solid Tumors. U.S.National Institutes of Health.
|
58 |
ClinicalTrials.gov (NCT04353102) A First-in-Human (FIH), Multicenter, Open-Label, Phase 1 Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of YH002 in Subjects With Advanced Solid Malignancies. U.S.National Institutes of Health.
|
59 |
ClinicalTrials.gov (NCT05017623) A Multicenter, Open-label, Phase 1 Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of YH003 in Subjects With Advanced Solid Tumors. U.S.National Institutes of Health.
|
60 |
Clinical pipeline report, company report or official report of Biontech
|
61 |
Clinical pipeline report, company report or official report of Dyve Biosciences
|
62 |
Clinical pipeline report, company report or official report of Purple
|
63 |
Clinical pipeline report, company report or official report of Biocytogen
|
64 |
Clinical pipeline report, company report or official report of Biocytogen
|
65 |
Clinical pipeline report, company report or official report of Biocytogen
|
|
|
|
|
|
|